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Distinct Biomarker Profiles and Clinical Characteristics in T1-T2
Glottic and Supraglottic Carcinomas
Jan E. Wachters, MD ; Emiel Kop, MD ; Lorian Slagter-Menkema, BSc; Mirjam Mastik, BSc;
Jacqueline E. van der Wal, MD, PhD†; Bert van der Vegt, MD, PhD; Geertruida H. de Bock, PhD;
Bernard F.A.M. van der Laan, MD, PhD‡; Ed Schuuring, PhD‡
Background: In early stage laryngeal squamous cell carcinoma (LSCC) radiotherapy with curative intent is a major treat-
ment modality. TNM classification is used to define patients eligible for radiotherapy. Studies in early stage glottic LSCC identi-
fied several predictive biomarkers associated with local control. However, we recently reported that this predictive value could
not be confirmed in supraglottic LSCC.
Objective: To examine whether clinical behavior and protein expression patterns of these biomarkers differ between
glottic and supraglottic LSCC.
Study Design: Retrospective cohort study.
Methods: Tumor tissue sections of 196 glottic and 80 supraglottic T1-T2 LSCC treated primarily with RT were assessed
immunohistochemically for expression of pAKT, Ki-67 and β-Catenin. Expression data of HIF-1α, CA-IX, OPN, FADD, pFADD,
Cyclin D1, Cortactin and EGFR in the same cohort of glottic and supraglottic LSCC, were retrieved from previously reported
data. The relationship between glottic and supraglottic sublocalization and clinicopathological, follow-up, and immunohisto-
chemical staining characteristics were evaluated using logistic regression and Cox regression analyses.
Results: Glottic LSCC were correlated with male gender (P = .001), hoarseness as a primary symptom (P < .001), T1
tumor stage (P < .001), negative lymph node status (P < .001), and an older age at presentation (P = .004). Supraglottic LSCC
patients developed more post-treatment distant metastasis when adjusted for gender, age, and T-status. While supraglottic
LSCC was associated with higher expression of HIF-1α (P = .001), Cortactin (P < .001), EGFR (P < .001), and Ki-67 (P = .027),
glottic LSCC demonstrated higher expression of CA-IX (P = .005) and Cyclin D1 (P = .001).
Conclusion: Differences in clinicopathological and immunohistochemical staining characteristics suggest that T1-T2
glottic and supraglottic LSCC should be considered as different entities.
Key Words: Biomarkers, head and neck squamous cell carcinoma, glottic laryngeal squamous cell carcinoma, supraglottic
laryngeal squamous cell carcinoma.
Level of Evidence: N/A.
Laryngoscope, 00:1–8, 2020
INTRODUCTION
Head and neck cancer encompasses a broad spectrum
of malignancies, and is responsible for 550,000 new cases
and 380,000 deaths worldwide annually.1 Histologically,
the vast majority (approximately 90%) concerns mucosal
squamous cell carcinomas. Head and neck squamous cell
carcinoma (HNSCC) is a heterogeneous group of malignan-
cies, involving multiple subsites. About 21% of all HNSCC
are located in the larynx.2 Squamous cell carcinoma of the
larynx (LSCC) originates from supraglottic, glottic, and
subglottic sites in 69%, 28%, and 1% respectively (2% over-
lapping/unknown).3
In early stage LSCC radiotherapy is a major treatment
modality. However, local control (LC) rates vary between
40% and 100% in early stage LSCC.4 Radiotherapy failure
frequently results in highly morbid salvage surgery. A major
wound complication rate of 60% and a pharyngocutaneous
fistula rate of 30% have been described.5
TNM staging, apparently, is of insufficient predictive
value toward radio response. In search for new predictive
markers in LSCC, immunohistochemical expression of
tumor-specific proteins has been investigated frequently.
The authors4,6–8 and others9–11 studied proteins such as
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those involved in cell cycle regulation, tumor hypoxia, and
cell adhesion. However, the predictive value of these
markers varied considerably. For instance, in separate
homogeneous cohorts of 91 glottic and 60 supraglottic T1-T2
LSCC treated with primarily radiotherapy, hypoxia markers
HIF-1α and CA-IX were predictive for LC in glottic LSCC,7
but not in supraglottic LSCC.4 More recently we found that
pFADD overexpression was associated with a significantly
improved LC rate in glottic LSCC,8 whereas in our sup-
raglottic cohort it was not.6 One explanation for this discrep-
ancy is that these LSCC sublocalizations represent other
entities, each with its own clinical and biological behavior.
As a consequence, the protein expression patterns might
differ.
In this study, we will compare the frequency of high/
low expression of hypoxia markers HIF-1α, CA-IX, and
OPN, the 11q13-related biomarkers FADD, pFADD,
Cyclin D1 and Cortactin, and EGFR in a large cohort of
pretreatment biopsies of 196 glottic and 80 supraglottic
T1-T2 LSCC. The expression of most of these markers was
studied previously in association with clinical outcome
upon radiotherapy in this cohort of glottic and supraglottic
early stage LSCC. The data on frequency of expression of
these markers were retrieved from previously published
studies.4,6–8,12 In addition, we selected three other bio-
markers from the literature because of their typical profile
in LSCC (pAKT, Ki-67, and β-Catenin)13 and performed
expression analysis by immunohistochemistry using the
same cohort of pretreatment biopsies of 196 glottic and
80 supraglottic T1-T2 LSCC.
MATERIALS AND METHODS
Patient and Biomarker Selection
A database was constructed with 1513 patients treated in
the University Medical Center Groningen for (pre-)malignant
laryngeal disease between 1990 and 2011. The following selec-
tion criteria were used, as reported previously4,6: histologically
confirmed squamous cell carcinoma restricted to the glottic and
supraglottic region; staged cT1 or cT2; curatively treated with
primarily radiotherapy with no other previous treatment; suffi-
cient formaldehyde-fixed paraffin-embedded (FFPE) pre-
treatment tumor material, resulting in a cohort of 650 patients.
Five patients were excluded because of a malignancy of the head
and neck region in their medical history, nine patients were
excluded because of the existence of a double tumor in the head
and neck region, and 11 patients were excluded because of che-
motherapy or other systemic treatment of malignancies before or
during treatment for their LSCC.
From 276 patients, sufficient FFPE tumor tissue was avail-
able, covering 196 glottic and 80 supraglottic LSCC patients
(Table I). The collection of patient data and tissue samples was
approved by the Medical Ethics Committee of our hospital.
The cohort of patients treated between 1990–2008 was
described in detail in previously reported studies on the expres-
sion of HIF-1α, CA-IX, OPN, FADD, pFADD, Cyclin D1, Cor-
tactin, and EGFR in relation to response to radiotherapy.4,6–8,12
TABLE I.












Gender Male 59 (73.8) 177 (90.3) 1 1
Female 21 (26.3) 19 (9.7) 3.32 (1.67–6.59)† 3.53 (1.37–9.13)†
Age (yr) <64 53 (66.3) 92 (46.9) 1 1
>64 27 (33.7) 104 (53.1) 0.45 (0.26–0.78)† 0.34 (0.15–0.77)†
Median (range) 62.0 (33–96) 65.0 (35–89)
Primary symptom Hoarse voice 39 (48.8) 191 (97.4) 1 1
Other 41 (51.3) 2 (0.5) 100.40 (23.30–432.52)‡ 128.40 (26.65–618.56)‡
Duration of complaint (wk) <22 42 (53.8) 94 (48.7) 1 NA
>22 36 (46.2) 99 (51.3) 0.81 (0.48–1.38)
Median (range) 18.0 (0–520) 24.0 (0–520)
T-status T1 22 (27.5) 100 (51.0) 1 1
T2 58 (72.5) 96 (49.0) 2.75 (1.56–4.83)‡ 2.98 (1.33–6.68)†
N-status N0 61 (76.3) 192 (98.0) 1 1
N+ 19 (23.8) 3 (1.5) 19.93 (5.70–69.67)‡ 8.54 (1.67–43.70)†
N-status N1 9 (11.3) 3 (1.5) NA NA
N2 9 (11.3) 0 (0.0)
N3 1 (1.3) 0 (0.0)
Nx 0 (0.0) 1 (0.5)




CI = confidence interval; LSCC = laryngeal squamous cell carcinoma; N = node; NA = not applicable; OR = odds ratio; T = tumor.
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For the expression analysis of pAKT, Ki-67, and β-Catenin, the
cohort was expanded with early stage LSCC patients treated
between 2009 and 2011.
Immunohistochemistry
First, hematoxylin and eosin staining was performed after
4-μm serial sections were cut, to evaluate whether sufficient
tumor material was available for immunohistochemistry.
Antigen retrieval was achieved by heating in a microwave in
preheated citrate buffer (pH 6.0) for 15 minutes at 100C, by incuba-
tion overnight in Tris–HCl (pH 9.0) at 80C, and by heating in a
microwave in preheated Tris/HCL buffer for 15 minutes at 100C,
respectively. Next, endogenous peroxidases were blocked for
30 minutes at room temperature (RT) with 0.3% H2O2. The slides
were incubated at RT for 1 hour with antibodies against pAKT
(1:50, clone 736E11, Cell Signaling Technology, Danvers, Massachu-
setts, USA), Ki-67 (1:350, Clone MIB-1, Dako, Glostrup, Denmark),
and β-Catenin (1:1,000, clone 14/B, BD Biosciences, San Jose,
California, USA). Subsequently, for pAKT immunostaining
Envision treatment was applied (Dako) for 30 minutes at RT. For
Ki-67 and β-Catenin stainings, secondary antibodies were applied
for 30 minutes at RT (1:100, RAMPO, Dako), followed by
tertiary antibodies, as well for 30 minutes at RT (1:100, GARPO,
Dako). The peroxidase reaction was performed by applying
3,30-diaminobenzide tetrachloride for 10 minutes, followed by
counterstaining with hematoxylin, dehydration, and mounting.
Evaluation of Immunohistochemical Staining
All slides were scored by two observers separately, blinded
for follow-up data. In general, in this study, protein expression is
classified as high when the percentage of positive tumor cells is
higher than the predefined cut-off.
For evaluation of cytoplasmic pAKT immunostaining,
expression levels (high or low) were defined using a cut-off of
Fig. 1. Positive staining for pAKT A, EGFR B, Ki-67 C, and β-Catenin D, in laryngeal squamous cell carcinoma. Original magnification, 200x.
[Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]
TABLE II.






HR (95%CI) Death HR (95%CI)
Death of Disease
HR (95% CI)
Non-adjusted estimate Glottic LSCC 1 1 1 1
Supraglottic LSCC 1.14 (0.68–1.90) 4.95 (1.49–16.50) † 1.33 (0.92–1.93) 0.54 (0.25–1.19)
Gender Glottic LSCC 1 1 1 1
Supraglottic LSCC 1.29 (0.77–2.17) 5.19 (1.53–17.65)† 1.41 (0.96–2.06) 0.40 (0.17—0.94)†
Age Glottic LSCC 1 1 1 1
Supraglottic LSCC 1.17 (0.69–1.97) 5.40 (1.56–18.64)† 1.61 (1.10–2.35)† 0.56 (0.25–1.26)
Primary symptom Glottic LSCC 1 1 1 1
Supraglottic LSCC 1.25 (0.67–2.34) 2.78 (0.58–13.44) 1.31 (0.83–2.06) 0.50 (0.17–1.47)
T-status Glottic LSCC 1 1 1 1
Supraglottic LSCC 1.02 (0.60–1.73) 5.14 (1.51–17.51) † 1.32 (0.91–1.91) 0.50 (0.23–1.11)
N-status Glottic LSCC 1 1 1 1
Supraglottic LSCC 0.91 (0.51–1.60) 2.93 (0.77–11.09) 1.23 (0.83–1.81) 0.70 (0.23–2.13)
*Cox regression analysis adjusted for gender, age, primary symptom, T-status and N-status.
†P < .05.
CI = confidence interval; LSCC = laryngeal squamous cell carcinoma; HR = hazard ratio.
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10% of tumor cells with positive expression, as reported previ-
ously in HNSCC.13–16 The evaluation of Ki-67 expression has
been performed using different cut-offs, varying from 10% to
60%.17–21 Therefore, Ki-67 expression was evaluated using the
median staining percentage (49%). Expression of β-Catenin was
scored on both membranous as well as cytoplasmic staining. For
membranous staining a cut-off percentage of 10% was used, as
reported previously.13 In case of β-Catenin cytoplasmic staining
any staining above background staining was considered positive
as reported earlier.11,22 Examples of pAKT, Ki-67, β-Catenin, and
EGFR immunostainings are shown in Figure 1A–D.
Expression data of HIF-1α, CA-IX, OPN, FADD, pFADD,
Cyclin D1, Cortactin, and EGFR in our two cohorts of glottic and
supraglottic LSCC were retrieved from our previous
studies.4,6–8,12,23 The used antibodies, the immunohistochemical
staining conditions, and the scoring criteria of the immunostainings
of all used biomarkers are summarized in Supplementary data,
Table S1.
TABLE III.






OR (95% CI)* Previously Reported
HIF-1α Low n (%) 45 (49.5) 13 (21.7) 1 Schrijvers 2008 161,
Wachters 2013 2154
High n (%) 46 (50.5) 47 (78.3) 3.54 (1.69–7.41)†
Median (range) 1.0 (0–60) 6.0 (0–50)
CA-IX Low n (%) 54 (59.3) 49 (81.7) 1 Schrijvers 2008 161,
Wachters 2013 2154
High n (%) 37 (40.7) 11 (18.3) 0.33 (0.15–0.71)†
Median (range) 10.0 (0–90) 1.0 (0–40)
OPN Low n (%) 69 (76.7) 40 (66.7) 1 Wachters 2013 2154
High n (%) 21 (23.3) 20 (33.3) 1.64 (0.80–3.40)
Median (range) 0.0 (0–50) 0.0 (0–80)
FADD Low n (%) 71 (77.2) 40 (66.7) 1 Schrijvers 2012 1220,
Wachters 2017 0000
High n (%) 21 (22.8) 20 (33.3) 1.69 (0.82–3.49)
Median (range) 2.0 (0–4) 2.0 (0–4)
pFADD Low n (%) 30 (32.6) 17 (28.3) 1 Schrijvers 2012 1220,
Wachters 2017 0000
High n (%) 62 (67.4) 43 (71.7) 1.22 (0.60–2.49)
Median (range) 80 (20–100) 80.0 (5–100)
Cyclin D1 Low n (%) 43 (49.4) 46 (78.0) 1 Glottic: Schrijvers 2012 122
High n (%) 44 (50.6) 13 (22.0) 0.28 (0.13–0.58)†
Median (range) 10.0 (0–85) 35.0 (0–95)
Cortactin Low n (%) 42 (51.9) 12 (20.3) 1 Glottic: Schrijvers 2012 122
High n (%) 39 (48.1) 47 (79.7) 4.22 (1.95–9.10)‡
Median (range) 20.0 (0–100) 65.0 (0–100)
pAKT Low n (%) 48 (34.3) 14 (22.6) 1 NA
High n (%) 92 (65.7) 48 (77.4) 1.79 (0.90–3.57)
Median (range) 50 (0–100) 70 (0–100)
EGFR Low n (%) 41 (47.1) 3 (5.9) 1 Supraglottic: Bruine
de Bruin 2019 1
High n (%) 46 (52.9) 48 (94.1) 14.26 (4.13–49.28)‡
Median (range) 2 (1–4) 2 (1–4)
Ki-67 Low n (%) 76 (56.7) 25 (39.7) 1 NA
High n (%) 58 (43.3) 38 (60.3) 1.99 (1.08–3.66)†
Median (range) 48.0 (15–86) 51 (4–89)
β-Catenin Low n (%) 6 (4.4) 4 (6.3) 1 NA
(membr.) High n (%) 131 (95.6) 60 (93.8) 0.69 (0.19–2.52)
Median (range) 75.0 (0–100) 76.5 (0–100)
β-Catenin Low n (%) 129 (94.2) 63 (98.4) 1 NA
(cytopl.) High n (%) 8 (5.8) 1 (1.6) 0.26 (0.03–2.09)
Median (range) 0 (0–1) 0 (0–1)
*Logistic regression analysis for the presence of supraglottic LSCC.
†P < .05.
‡P < .001.
CI = confidence interval; LSCC = laryngeal squamous cell carcinoma; OR = odds ratio; NA not applicable.
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Statistical Analysis
All statistical analyses were performed using the SPSS
23.0 software (IBM, Armonk, New York, USA). For analyzing
relations between clinicopathological characteristics and immu-
nohistochemical staining characteristics on the one side and
glottic/supraglottic LSCC sublocalization on the other side, uni-
and multivariate logistic regression analyses were used. Follow-
up data were analyzed using uni- and bivariate Cox regression
analyses. P-values of <.05 were considered to be statistically
significant.
RESULTS
Differences in Clinicopathological and Follow-up
Data in T1-T2 Glottic and Supraglottic LSCC
We compared common clinicopathological and follow-
up data observed in relation with tumor sublocalization in
our cohort of pretreatment biopsies of 196 glottic and
80 supraglottic LSCC patients (Table I). This analysis rev-
ealed that the duration of complaints was not correlated
significantly with LSCC sublocalization (P = .414). How-
ever, male gender (P = .001), hoarseness as a primary
symptom (P < .001), T1 tumor stage (P < .001), negative
lymph node status (P < .001), and an older age of tumor
presentation (P = .004) were statistically significantly
correlated with glottic sublocalization. On multivariate
logistic analysis these findings remained statistically sig-
nificant (Table I).
Both LSCC sublocalizations demonstrated a similar
number of patients with locoregional recurrences (see
Supporting Information, Table S2). Adjusted bivariate Cox
regression analyses revealed no significant difference in the
case of locoregional recurrence (Table II). Patients with
supraglottic LSCC developed more distant metastasis after
initial diagnosis/treatment (P = .009), losing significance
when adjusted for primary symptom (P = .203), and N-status
(P = .114). More supraglottic LSCC patients died, which
was only significant when adjusted for age (P = .015).
Significance of death of disease (DOD) was present only
when additionally corrected for gender (P = .035).
Comparison of Expression Profiles of Biomarkers
Associated with Clinical Outcome Between
Glottic and Supraglottic LSCC
In order to validate differences between glottic and
supraglottic T1-T2 LSCC, we compared the frequency of
expression of these 11 selected biomarkers (pAKT, Ki-67,
β-Catenin, HIF-1α, CA-IX, OPN, FADD, pFADD, Cyclin
D1, Cortactin, and EGFR), reported as potential prognostic
or predictive markers toward clinical outcome in LSCC
(summarized in Table III). The percentage of tumor cells
with high expression in both the glottic and supraglottic
sublocalization was similar for OPN, FADD, pFADD,
pAKT, and β-Catenin. The percentage of supraglottic
LSCC with high expression of HIF-1α, Cortactin, EGFR,
and Ki-67 was significantly higher, compared to glottic
LSCC (P = .001, P < .001, P < .001, P = .027, respectively).
On the other hand, expression of CA-IX and Cyclin D1 was
significantly increased in glottic LSCC compared to sup-
raglottic LSCC (P = .005, P = .001, respectively).
DISCUSSION
Despite many studies on the prognostic and/or predic-
tive value of immunohistochemical biomarkers in HNSCC
cohorts, conflicting and divergent results keep these bio-
markers from being incorporated in daily strategies. This
might be explained by population diversity in TNM stages,
immunohistochemical techniques, staining evaluation
methodologies, and anatomical tumor sublocalizations.24–26
Previously, we studied the association between local
control and expression of several markers in separate
homogeneous cohorts of T1-T2 glottic and supraglottic
LSCC, all treated with radiotherapy only. This associa-
tion with some markers observed in the glottic cohort,7,8
could not be confirmed in the supraglottic cohort.4,6
Recently, we found that pATM expression was associated
with local control in supraglottic but not in glottic
LSCC.27 These observations suggested that within these
tumor sublocalizations, clinical and biological behavior,
and hence protein expression patterns might differ.
In this study we analyzed both the clinicopathological
characteristics and the differences in frequency of high
expression of these biomarkers in two homogeneous, well-
defined cohorts of 196 glottic and 80 supraglottic LSCC,
all diagnosed and treated at the same institute. To circum-
vent differences as a result of technical issues, all tissue
samples were collected from the same cohort, immunohis-
tochemistry of all markers was performed in the same lab
using similar conditions and all immunostainings were
evaluated using the same scoring criteria as previously
defined (see Supporting Information, Table S1).4,7,8,12,13,23
From an epidemiological perspective, male gender was
significantly more dominant in the glottic than in the sup-
raglottic LSCC patients. This finding is in concordance with
other studies,28,29 whereas in several studies gender was not
related with tumor sublocalization.30,31 Geographical differ-
ences in the use of alcohol between both sexes are known
confounders.32 Moreover, compared to the (sub)glottis, the
supraglottis is exposed to a relatively higher degree to
ingested agents and to a lesser degree to inhaled agents,33
suggesting that etiological factors, like the use of alcohol and
tobacco, might have distinguishable epidemiological effects.
Because of the notoriously unreliable and frequently lacking
data on the use of tobacco and alcohol in our cohorts, these
characteristics were not analyzed in our study.
In the literature differences between the age at
which early stage glottic and supraglottic LSCC was diag-
nosed have not been described. In our study both the
median age and mean age (65.19 and 62.04, respectively,
data not shown) were 3 years higher in glottic LSCC
patients. Significantly more patients in our supraglottic
cohort died during our follow-up period, which is in agree-
ment with the literature,3 although disease-related death
rates were similar (see Supporting Information,
Table S2). However, in both glottic and supraglottic
LSCC only a minority died of disease-related causes.
From a clinical perspective, differences between
glottic and supraglottic LSCC can be pointed out as well.
Relatively small mucous membrane disruptions on a
glottic level produce vibratory disturbances of the involved
vocal fold during speech, hence hoarseness in the patient,
whereas comparable mucous membrane disturbances on a
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supraglottic level can remain unnoticed or misinterpreted
by the patient for a longer period of time.34 This is in good
agreement with the observation that hoarseness was a sig-
nificantly more frequently experienced primary symptom
in our glottic LSCC cohort. Additionally, it can explain the
significantly higher T-stage at presentation in our sup-
raglottic cohort.
Moreover, already on an early embryological basis,
the glottic and supraglottic larynx have distinguishable
origins. The glottic and subglottic larynx are derived from
the sixth branchial arch and the supraglottis from the
third and fourth branchial arches.34,35 The supraglottic
compartment ultimately develops a rich lymphatic net-
work and, with relatively few anatomical barriers, forms
a rather easy entrance for locoregional tumor spread.
Tumor spread in the glottic compartment, however, is
hampered by elastic layers and a more limited network of
lymphatics.36 The observed higher lymph node status at
diagnosis in supraglottic T1-T2 LSCC as compared to
glottic LSCC is in agreement with this organic perspec-
tive and with the literature as well.37
On a molecular level, the literature demonstrates
some clues that protein expression profiles between glottic
and supraglottic LSCC might differ. One study, using a
relatively small series of 35 glottic and 25 supraglottic
T1-T4 N0-N+ LSCC, revealed a significantly higher EGFR
and RXRa expression in glottic LSCC, whereas expression
of NF-kB and Cox2 were similar in both supraglottic and
glottic LSCC.38 Another study showed a decreased expres-
sion of β-Catenin in supraglottic LSCC, but no difference
regarding ILK, pAKT, E-Cadherin, Vimentin, AR, and
Er-b).13 These findings suggested the existence of distin-
guishable protein expression profiles in glottic and
supraglottic LSCC. On the other hand, α-Catenin, CD44,
hyaluronan, p53, and Bcl-2 was not correlated with tumor
sublocalization within 136 glottic and 62 supraglottic
Tis-T2 LSCC cohort.36
In the present paper, we selected 11 biomarkers, fre-
quently reported in LSCC/HNSCC and often reported to be
associated with clinical outcome.4,6–8,23,39 Differential
expression between glottic and supraglottic LSCC was
observed for six markers (HIF-1α, CA-IX, Cyclin D1, Cor-
tactin, EGFR, and Ki-67) (Table III). Tumor hypoxia is an
extensively studied process in HNSCC and has been shown
to induce genetic instability, tumor cell aggression, and
treatment failure.40,41 Predominantly, endogenous hypoxia
markers HIF-1α and its down-stream upregulated intracel-
lular pH regulating CA-IX have been under investigation
concerning their relation with survival and locoregional
control.40 We observed that the number of cases with
expression of both HIF-1α and CA-IX was significantly dif-
ferent between glottic and supraglottic LSCC (Table III). In
the literature, expression of CA-IX was not investigated in
glottic and supraglottic LSCC separately, whereas two
reports on expression of HIF-1α did not find a difference
between these sublocalizations.42,43 This discordance with
our data might be explained by the fact that these two stud-
ies are composed of T1-T4 LSCC with a relatively low num-
ber of T1-T2 cases (n = 41 and n = 63, respectively). Both
studies used a cut-off value of 10%. Our predetermined cut-
off value was 0.5%, as in our earlier studies, based on its
relation with treatment response. Yet, when a cut-off value
of 10% was applied, results remained similar (HR 2.88 CI,
1.24–6.69, P = .014, data not shown). The distribution of
the expression of hypoxia markers is a good explanation
that the hypoxia markers HIF-1α and CA-IX were predic-
tive for local control in glottic LSCC,7 but not in sup-
raglottic LSCC.4 Because tumor hypoxia can be
counteracted by breathing carbogen (98% O2 and 2% CO2)
and nicotinamide (a vasoactive drug) during radiotherapy44
to improve treatment response, the localization of squa-
mous cell carcinomas in the larynx should be taken into
account in treatment decision making.
In HNSCC, amplification of chromosome region
11q13.3 is a frequently observed event45,46 and is associ-
ated with poor prognosis.47 Genes for FADD, Cyclin D1,
and Cortactin are located within this region, resulting in
frequent overexpression in almost all HNSCC with this
amplification.48 Although FADD and pFADD expression
did not show significant differences in our glottic and sup-
raglottic cohort, Cyclin D1 and Cortactin did. Comparative
studies on FADD, pFADD, and Cortactin expression in
glottic and supraglottic LSCC separately have not been
published before, other than our previous publications.6,8
Several studies on Cyclin D1 expression do report on glottic
and supraglottic LSCC separately.49–53 None of these stud-
ies revealed expression differences between tumor sub-
localization, but the number of T1-T2 LSCC cases in most
of these study populations was rather small (n = 46, n = 75,
n = 38, n = 21, and n = 8, respectively). Evaluation methods
and cut-off percentages in the literature referred to above,
differed (three-point scale, immunoreactive score, 5% cut-
off, 5-point scale, 10% cut-off, respectively). As in previous
studies in LSCC, we utilized a cut-off of 32.5%.8
The AKT-pathway is a complex signal transduction
pathway that promotes cell cycle regulation in response to
extracellular signals. Both pAKT and EGFR are key pro-
teins in this pathway and the corresponding protein
expression has been demonstrated to be of clinical signifi-
cance in HNSCC.54,55 For EGFR staining we utilized the
methods of Pattje et al.23 Complete circular membranous
staining was considered high expression and no or incom-
plete circular membranous staining was considered low
expression. Four reports analyzed the expression of EGFR
in the LSCC sublocalizations separately, all using different
staining evaluation methodologies.38,52,56,57 Only one pub-
lication described a significantly increased frequency of
tumors with high expression of EGFR in glottic LSCC.38
In our cohorts, a significantly increased frequency of cases
with high expression of EGFR was found in supraglottic
LSCC. The population of Kourelis et al. was, however, too
small to draw firm conclusions, containing only 18 glottic
and 12 supraglottic early stage LSCC. Regarding the
expression of pAKT, only Goulioumis et al. evaluated
glottic and supraglottic LSCC separately and described no
significantly differing expression pattern,13 which is in
agreement with our results. Cetuximab, a monoclonal anti-
body targeting the extracellular domain of EGFR, has been
in use in clinical praxis in advanced stage HNSCC.58 As
high expression of EGFR was found particularly in sup-
raglottic LSCC, anti-EGFR treatment might be more effec-
tive in LSCC originating from the supraglottic larynx.
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Ki-67 is a good marker to quantify the degree of pro-
liferative activity in neoplastic cells, since nuclear Ki-67
is present in all phases of the cell cycle, but not in the G0
phase (resting cells).59 The nuclear expression of Ki-67
was significantly higher in our supraglottic cohort com-
pared to our glottic cohort, confirming the findings of
Tamas et al.60 There are publications without significant
association between Ki-67 expression and LSCC sub-
localization as well.61,62 Study populations existed of
T1-T4 or unknown stage LSCC and differing evaluation
methods were used, complicating a firm comparison.
In LSCC, loss of expression of the membrane protein
β-Catenin, has been associated with tumor dedifferentia-
tion and a decrease in disease-specific survival.22,63 In a
group of 46 glottic and 12 early stage supraglottic LSCC
loss of membranous β-Catenin expression was associated
with supraglottic sublocalization.13 Moreover, a combined
cytoplasmic and membranous β-Catenin expression was
associated with supraglottic sublocalization in a popula-
tion of 32 LSCC of unknown TNM stage.11 In our LSCC
cohorts β-Catenin did not demonstrate a sublocalizational
difference, following the results of Greco et al.22
CONCLUSION
Our data on protein expression patterns and clinico-
pathological features in a well-defined cohort of 276 early
stage LSCC suggest that supraglottic and glottic LSCC
should be considered as different entities. This is in
agreement with differences observed in tumor response
upon radiotherapy and clinical outcome. Our findings
imply that results of reported studies that have included
both glottic and supraglottic LSCC should be interpreted
with caution. In future studies, we strongly recommend
to evaluate supraglottic and glottic LSCC separately.
Ultimately, these plausible biological differences between
glottic and supraglottic LSCC may lead to more differen-
tial treatment schedules in (subpopulations of) glottic
and supraglottic LSCC.
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